Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer

MLA

Ingolf Schimke, et al. “Matrix Metalloproteinase Inhibitor RO 28-2653 Decreases Liver Metastasis by Reduction of MMP-2 and MMP-9 Concentration in BOP-Induced Ductal Pancreatic Cancer in Syrian Hamsters: Inhibition of Matrix Metalloproteinases in Pancreatic Cancer.” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 75, Dec. 2006, pp. 429–34. EBSCOhost, https://doi.org/10.1016/j.plefa.2006.08.004.

APA

Ingolf Schimke, F. A. Wenger, M. Kilian, I. Heukamp, M. Hanel, M. Ahlgrimm, J. I. Gregor, Andreas Ommer, Martin K. Walz, Glen Kristiansen, & Christoph A. Jacobi. (2006). Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75, 429–434. https://doi.org/10.1016/j.plefa.2006.08.004

Chicago

Ingolf Schimke, F. A. Wenger, M. Kilian, I. Heukamp, M. Hanel, M. Ahlgrimm, J. I. Gregor, et al. 2006. “Matrix Metalloproteinase Inhibitor RO 28-2653 Decreases Liver Metastasis by Reduction of MMP-2 and MMP-9 Concentration in BOP-Induced Ductal Pancreatic Cancer in Syrian Hamsters: Inhibition of Matrix Metalloproteinases in Pancreatic Cancer.” Prostaglandins, Leukotrienes and Essential Fatty Acids 75 (December): 429–34. doi:10.1016/j.plefa.2006.08.004.